Uptake-release by MSCs of a cationic platinum(II) complex active in vitro on human malignant cancer cell lines

Biomed Pharmacother. 2018 Dec:108:111-118. doi: 10.1016/j.biopha.2018.09.040. Epub 2018 Sep 12.

Abstract

In this study, the in vitro stability of cisplatin (CisPt) and cationic platinum(II)-complex (caPt(II)-complex) and their in vitro activity (antiproliferative and anti-angiogenic properties) were investigated against three aggressive human tumor cell lines. caPt(II)-complex shown a high stability until 9 days of treatment and displayed a significant and higher activity than CisPt against both NCI-H28 mesothelioma (19.37 ± 9.57 μM versus 34.66 ± 7.65 μM for CisPt) and U87 MG glioblastoma (19.85 ± 0.97 μM versus 54.14 ± 3.19 for CisPt). Mesenchymal Stromal Cells (AT-MSCs) showed a significant different sensitivity (IC50 = 71.9 ± 15.1 μM for caPt(II)-complex and 8.7 ± 4.5 μM for CisPt) to the antiproliferative activity of caPt(II)-complex and CisPt. The ability of MSCs to uptake both the drugs in a similar amount of 2.49 pM /cell, suggested a possible development of new therapies based on cell mediated drug delivery.

Keywords: Cationic platinum (II)-complex; Cisplatin; Drug delivery; Glioblastoma; Mesenchymal stromal cells; Mesothelioma.

MeSH terms

  • Adipose Tissue / cytology
  • Adult
  • Antineoplastic Agents / pharmacology
  • Cations
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Cisplatin / pharmacology*
  • Humans
  • Mesenchymal Stem Cells / drug effects
  • Mesenchymal Stem Cells / metabolism*
  • Neoplasms / metabolism*
  • Neoplasms / pathology*
  • Neovascularization, Physiologic / drug effects
  • Platinum / pharmacology*
  • Temperature

Substances

  • Antineoplastic Agents
  • Cations
  • Platinum
  • Cisplatin